- Conditions: Lymphoblastic Leukemia, Acute, Childhood; Myelogenous Leukemia, Acute, Childhood
Interventions: Drug: Azacitidine; Drug: Fludarabine; Drug: Cytarabine
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium; Gateway for Cancer Research; USC/Norris Comprehensive Cancer Center
Not yet recruiting - verified May 2013 - Condition: Neuroblastoma
Interventions: Drug: cyclophosphamide; Drug: topotecan; Biological: hu14.18K322A; Procedure: peripheral blood stem cell harvest; Procedure: surgical resection; Drug: cisplatin; Drug: etoposide; Drug: doxorubicin; Drug: vincristine; Drug: busulfan; Drug: melphalan; Biological: peripheral blood stem cell transplantation; Biological: natural killer cell infusion; Radiation: radiation therapy; Biological: GM-CSF; Biological: G-CSF; Drug: mesna; Drug: levetiracetam; Biological: interleukin-2; Drug: Isotretinoin
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; Cookies for Kids' Cancer
Not yet recruiting - verified May 2013 - Condition: Congestive Heart Failure
Interventions: Drug: D-ribose; Other: Placebo
Sponsors: RiboCor, Inc.; RiboCor, Inc.
Not yet recruiting - verified May 2013 - Conditions: Human Immunodeficiency Virus (HIV); Acquired Immunodeficiency Syndrome (AIDS)
Intervention: Other: Questionnaire
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Not yet recruiting - verified May 2013 - Conditions: Acquired Immune Deficiency Syndrome (AIDS); HIV Infections
Intervention: Drug: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF)
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Condition: Multiple Myeloma
Intervention:
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AbbVie
Recruiting - verified April 2013 - Condition: Facial Angiofibroma
Intervention: Drug: Rapamune
Sponsors: Le Bonheur Children's Hospital; Le Bonheur Children's Hospital; Pfizer; University of Tennessee Health Science Center
Not yet recruiting - verified May 2013 - Condition: Chronic Idiopathic Constipation
Interventions: Drug: Elobixibat 10 mg; Drug: Elobixibat 5 mg; Drug: Placebo
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Recruiting - verified May 2013 - Condition: Hypertension, Pulmonary
Interventions: Drug: Tadalafil; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2013 - Condition: Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Interventions: Drug: Ivacaftor; Drug: Lumacaftor; Drug: Ivacaftor Placebo; Drug: Lumacaftor Placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2013 - Condition: Pneumonia, Bacterial
Interventions: Drug: Amikacin Inhalation Solution (BAY41-6551); Drug: Aerosolized Placebo
Sponsors: Bayer; Bayer; Nektar Therapeutics; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Sickle Cell Disease
Interventions: Drug: Prasugrel; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Daiichi Sankyo Inc.
Recruiting - verified May 2013 - Condition: HIV Infections
Intervention: Drug: Raltegravir
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2013 - Condition: Squamous Non Small Cell Lung Cancer
Interventions: Drug: Necitumumab; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Colorectal Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: leucovorin; Drug: 5-fluorouracil; Drug: irinotecan; Drug: oxaliplatin; Drug: capecitabine [Xeloda]; Drug: fluoropyrimidine-based chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Interventions: Drug: VX-509; Drug: VX-509 matching placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2013 - Condition: Triple Negative Breast Cancer
Interventions: Drug: Tivozanib Hydrochloride; Drug: paclitaxel
Sponsors: AVEO Pharmaceuticals, Inc.; AVEO Pharmaceuticals, Inc.; Astellas Pharma Inc
Recruiting - verified April 2013 - Conditions: Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS)
Intervention: Drug: Treosulfan
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program; Resource for Clinical Investigation in Blood and Marrow Transplantation (RCI BMT); Pediatric Blood and Marrow Transplant Consortium; St. Baldrick's Foundation; medac GmbH
Not yet recruiting - verified May 2013 - Condition: Leukemia Lymphocytic Chronic B-Cell
Interventions: Drug: CC-292; Drug: Rituximab
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2013 - Condition: Alzheimer's Disease
Interventions: Drug: AC-1204; Drug: Placebo
Sponsors: Accera, Inc.; Accera, Inc.
Recruiting - verified May 2013 - Conditions: Diabetes Mellitus, Non-Insulin-Dependent; High Risk for Cardiovascular Event
Interventions: Drug: Dapagliflozin 10 mg; Drug: Placebo tablet
Sponsors: AstraZeneca; AstraZeneca; Bristol-Myers Squibb; The TIMI Study Group; Hadassah Medical Organization
Recruiting - verified May 2013 - Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: tivantinib; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Small Cell Lung Carcinoma
Interventions: Drug: LY2940680; Drug: Carboplatin; Drug: Etoposide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Binge Eating Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013 - Condition: Diabetic Nephropathy
Interventions: Drug: PF-04634817; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Pediatric Growth Hormone Deficiency
Intervention: Drug: Experimental: VRS-317
Sponsors: Versartis Inc.; Versartis Inc.
Recruiting - verified May 2013 - Conditions: Recurrent Melanoma; Recurrent Thyroid Cancer; Thyroid Gland Medullary Carcinoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: cabozantinib-s-malate; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Interventions: Drug: sarilumab SAR153191 (REGN88); Other: placebo
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified May 2013 - Condition: Non-small Cell Lung Cancer(NSCLC)
Interventions: Drug: AT13387; Drug: Crizotinib
Sponsors: Astex Pharmaceuticals; Astex Pharmaceuticals
Recruiting - verified April 2013 - Condition: Malignant Melanoma
Intervention: Biological: Ipilimumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013 - Condition: Cystic Fibrosis
Interventions: Biological: KB001-A; Biological: Placebo Comparator
Sponsors: KaloBios Pharmaceuticals; KaloBios Pharmaceuticals
Recruiting - verified May 2013 - Condition: Clostridium Difficile-Associated Diarrhea (CDAD)
Interventions: Drug: fidaxomicin; Drug: placebo
Sponsors: Optimer Pharmaceuticals; Optimer Pharmaceuticals
Recruiting - verified May 2013 - Condition: Adult Attention Deficit Hyperactivity Disorder
Interventions: Drug: SEP-225289; Drug: SEP-225289; Drug: Placebo
Sponsors: Sunovion; Sunovion
Recruiting - verified May 2013 - Condition: Malignant Melanoma
Interventions: Drug: vemurafenib; Drug: Placebo; Drug: GDC-0973
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Tardive Dyskinesia
Interventions: Drug: NBI-98854; Drug: NBI-98854; Drug: Placebo
Sponsors: Neurocrine Biosciences; Neurocrine Biosciences
Recruiting - verified May 2013 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102; Drug: MK-3102 Placebo; Drug: Glimepiride; Drug: Glimepiride Placebo; Drug: Metformin; Drug: Insulin Glargine
Sponsors: Merck; Merck
Recruiting - verified April 2013 - Condition: Infertility
Interventions: Drug: Gonal-f; Drug: AFOLIA
Sponsors: Finox AG; Finox AG
Not yet recruiting - verified April 2013 - Condition: Prostate Cancer
Interventions: Drug: AT13387 and abiraterone; Drug: AT13387 alone
Sponsors: Astex Pharmaceuticals; Astex Pharmaceuticals
Recruiting - verified April 2013 - Condition: Obsessive-Compulsive Disorder
Interventions: Drug: bitopertin; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2013 - Condition: Arthritis, Rheumatoid
Interventions: Drug: BI 695500; Drug: BI 695500; Drug: rituximab; Drug: rituximab; Drug: rituximab
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Conditions: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
Interventions: Drug: LY2228820; Drug: Carboplatin; Drug: Placebo; Drug: Gemcitabine
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Infusion Reactions
Intervention: Drug: unlicensed cord blood units
Sponsors: New York Blood Center; New York Blood Center
Recruiting - verified May 2013 - Condition: Cystic Fibrosis
Interventions: Drug: Aztreonam for Inhalation Solution (AZLI); Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified July 2012 - Conditions: Inflammation; Rheumatoid Arthritis
Interventions: Drug: NNC0109-0012; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013 - Conditions: Inflammation; Rheumatoid Arthritis
Interventions: Drug: NNC0109-0012; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013 - Condition: Metastatic Breast Cancer HR+, HER2-
Interventions: Drug: Fulvestrant; Drug: BKM120; Drug: BKM120 matching placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Conditions: Primary Myelofibrosis; Post Polycythemia Vera Fibrosis; Post Essential Thrombocythemia Myelofibrosis
Intervention: Drug: INCB039110
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified May 2013 - Condition: HIV Infections
Interventions: Drug: Lamivudine/zidovudine; Drug: Lopinavir/ritonavir; Drug: Efavirenz; Drug: Raltegravir
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2013 - Condition: Eisenmenger
Intervention: Other: Management
Sponsors: Actelion; Actelion
Recruiting - verified May 2013 - Condition: Healthy
Intervention:
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified May 2013 - Condition: Solid Tumors
Interventions: Drug: Iniparib (SAR240550/BSI-201); Drug: Carboplatin; Drug: Doxorubicin HCL liposome injection; Drug: Gemcitabine; Drug: Irinotecan; Drug: Paclitaxel; Drug: Topotecan
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013 - Conditions: Ulcerative Colitis; Left-sided Ulcerative Colitis; Distal Ulcerative Colitis
Interventions: Drug: Zoenasa-1:4; Drug: Mesalamine Enema
Sponsors: Altheus Therapeutics, Inc.; Altheus Therapeutics, Inc.
Recruiting - verified May 2013 - Condition: Prostate Cancer
Interventions: Drug: cabazitaxel, prednisone, custirsen sodium; Drug: cabazitaxel, prednisone
Sponsors: OncoGenex Technologies; OncoGenex Technologies; Teva Pharmaceutical Industries
Recruiting - verified May 2013 - Condition: Huntington's Disease
Intervention:
Sponsors: CHDI Foundation, Inc.; CHDI Foundation, Inc.
Recruiting - verified May 2013 - Condition: Irritable Bowel Syndrome
Interventions: Drug: JNJ-27018966; Drug: Placebo
Sponsors: Furiex Pharmaceuticals, Inc; Furiex Pharmaceuticals, Inc
Recruiting - verified May 2013 - Condition: Attention-deficit/Hyperactivity Disorder
Interventions: Drug: Lisdexamfetamine dimesylate; Drug: Methylphenidate Hydrochloride; Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013 - Condition: Schizophrenia
Interventions: Drug: AMG 747; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Conditions: Autism; Children
Intervention:
Sponsors: Le Bonheur Children's Hospital; Le Bonheur Children's Hospital; University of Tennessee Health Science Center
Recruiting - verified May 2013 - Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: liraglutide; Drug: placebo; Drug: metformin
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013 - Condition: Colorectal Neoplasms
Intervention: Drug: Regorafenib (BAY73-4506)
Sponsors: Bayer; Bayer
Available - verified May 2013 - Condition: Advanced Parkinson's Disease
Interventions: Drug: Rotigotine; Drug: Placebo
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2013 - Condition: Schizophrenia
Interventions: Drug: PPM3 175 mg eq.; Drug: PPM3 263 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: Placebo (20% Intralipid emulsion)
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2013 - Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX); Biological: Placebo + Methotrexate (MTX)
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified April 2013 - Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX); Biological: Placebo + Methotrexate (MTX)
Sponsors: UCB, Inc.; UCB Pharma SA
Recruiting - verified April 2013 - Condition: Schizophrenia
Interventions: Drug: PP3M 175 mg eq.; Drug: PP3M 263 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: Placebo (20% Intralipid); Drug: PP1M 50 mg eq.; Drug: PP1M 75 mg eq.; Drug: PP1M 100 mg eq.; Drug: PP1M 150 mg eq.
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013 - Condition: Malignant Melanoma
Intervention: Drug: vemurafenib
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Tophaceous Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2013 - Condition: Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2013 - Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Conditions: Liposarcoma; Surgically Unresectable Liposarcoma; Metastatic Liposarcoma
Intervention: Drug: pazopanib
Sponsors: ACORN Research, LLC; ACORN Research, LLC; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2013 - Condition: Cervical Dystonia
Intervention: Biological: Xeomin®
Sponsors: Merz Pharmaceuticals, LLC; Merz Pharmaceuticals, LLC
Recruiting - verified April 2013 - Condition: Lupus Nephritis
Interventions: Drug: BIIB023; Drug: Placebo
Sponsors: Biogen Idec; Biogen Idec; Biogen Idec Australia Pty Ltd; Biogen Idec Research Ltd.; Biogen Idec MA Inc.
Recruiting - verified April 2013 - Condition: HER2 Negative Breast Cancer
Interventions: Biological: NeuVax vaccine; Biological: Leukine (sargramostim, GM-CSF) and water for injection
Sponsors: Galena Biopharma, Inc.; Galena Biopharma, Inc.
Recruiting - verified May 2013 - Condition: Central Nervous System
Intervention: Drug: perampanel
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified May 2013 - Condition: Non Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dacomitinib Plus Blinded Doxycycline or Placebo; Drug: Dacomitinib Plus Probiotic Plus Topical Alclometasone cream; Drug: Dacomitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Abdominal Neuroblastoma
Intervention: Radiation: Intensity Modulated Radiation Therapy (IMRT)
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; Mayo Clinic
Recruiting - verified May 2013 - Condition: Depression Disorder, Major
Interventions: Drug: RO4917523; Drug: RO4917523; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Major Depressive Disorder
Interventions: Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate ); Drug: Antidepressant + Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013 - Condition: Major Depressive Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate ); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013 - Condition: Breast Cancer
Interventions: Drug: fulvestrant; Drug: GDC-0941; Drug: GDC-0980; Drug: placebo; Drug: GDC-0941; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified May 2013 - Condition: Lymphoblastic Lymphoma
Interventions: Drug: prednisone, vincristine, daunorubicin, PEG-asparaginase, methotrexate, hydrocortisone, cytarabine (IT-MH)A treatment, cyclophosphamide, cytarabine, thioguanine; Drug: PEG- asparaginase, High-Dose Methotrexate (HD-MTX) and Mercaptopurine; Drug: Dexamethasone, Doxorubicin; Vincristine; Mercaptopurine; PEG- Asparaginase, Cyclophosphamide, and Cytarabine; Drug: dexamethasone, cytarabine, etoposide, pegaspargase, clofarabine, cyclophosphamide; Drug: Intrathecal chemotherapy
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; National University, Singapore
Recruiting - verified May 2013 - Condition: Craniopharyngioma
Interventions: Procedure: Radical Surgery or Limited Surgery; Radiation: Proton Therapy
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified April 2013 - Condition: Uncontrolled Hypertension
Intervention: Device: Renal denervation (Symplicity Catheter System)
Sponsors: Medtronic Vascular; Medtronic Vascular
Recruiting - verified May 2013 - Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: ocrelizumab; Drug: Rebif; Drug: ocrelizumab placebo; Drug: Rebif placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Traumatic Brain Injury
Intervention:
Sponsors: Emory University; Emory University; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2013 - Condition: Depression, Bipolar
Interventions: Drug: Placebo; Drug: Cariprazine; Drug: Cariprazine; Drug: Cariprazine
Sponsors: Forest Laboratories; Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified April 2013 - Condition: Bipolar 1 Disorder
Interventions: Drug: asenapine; Drug: placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Conditions: Cardiovascular Disease; Diabetes Mellitus, Type 2
Interventions: Drug: Dulaglutide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Acute Schizophrenia
Interventions: Drug: OPC-34712; Drug: OPC-34712; Drug: OPC-34712; Drug: Placebo
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified May 2013 - Condition: Schizophrenia
Intervention: Drug: OPC-34712
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified May 2013 - Conditions: Brain and Central Nervous System Tumors; Cognitive/Functional Effects; Fatigue; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment
Interventions: Drug: modafinil; Other: placebo
Sponsors: University of South Florida; University of South Florida; National Cancer Institute (NCI)
Recruiting - verified September 2011 - Condition: Major Depressive Disorder
Interventions: Drug: Desvenlafaxine Succinate Sustained-Release; Drug: Desvenlafaxine Succinate Sustained-Release; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Condition: Major Depressive Disorder
Interventions: Drug: desvenlafaxine succinate sustained release; Drug: fluoxetine; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Condition: Muscular Atrophy
Interventions: Drug: LY2495655; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Conditions: Dystonia; Voice Disorders
Intervention:
Sponsors: Emory University; Hyder A. Jinnah, MD, PhD; National Institute of Neurological Disorders and Stroke (NINDS); Office of Rare Diseases (ORD); Allergan; Dystonia Study Group
Recruiting - verified May 2013 - Conditions: Hematological Malignancies; Certain Lysosomal Storage and Peroxisomal Enzyme Deficiency Disorders; Hurler Syndrome (MPS I); Krabbe Disease (Globoid Leukodystrophy); X-linked Adrenoleukodystrophy; Primary Immunodeficiency Diseases; Bone Marrow Failure; Beta-thalassemia
Intervention: Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified April 2013 - Condition: Normal and Diseased Tissue and Body Fluids Samples
Intervention:
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified May 2013 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Standard of care treatment
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Conditions: Cancer; Hematologic Malignancies; Multiple Myeloma; Oncology; Bone Metastases; Multiple Myeloma Bone Lesions
Interventions: Drug: Denosumab; Drug: Zoledronic acid
Sponsors: Amgen; Amgen; Daiichi Sankyo Inc.
Recruiting - verified May 2013 - Condition: Cardiovascular Disease, Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: etanercept
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Conditions: Advanced Prostate Cancer; Prostatic Neoplasms
Intervention: Biological: sipuleucel-T
Sponsors: Dendreon; Dendreon
Recruiting - verified May 2013 - Condition: Symptomatic Severe Aortic Stenosis
Interventions: Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: AVR with a surgical heart valve; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: AVR with a surgical heart valve; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis
Sponsors: Edwards Lifesciences; Edwards Lifesciences
Recruiting - verified April 2013 - Condition: Bipolar Disorder, Pediatric
Interventions: Drug: asenapine; Drug: Placebo to match asenapine; Drug: Rescue medication
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Colorectal Cancer
Interventions: Procedure: Colonoscopy; Procedure: FIT
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2013 - Conditions: Childhood High-grade Cerebellar Astrocytoma; Childhood High-grade Cerebral Astrocytoma; Childhood Spinal Cord Neoplasm; Untreated Childhood Brain Stem Glioma; Untreated Childhood Cerebral Astrocytoma
Interventions: Drug: vorinostat; Biological: bevacizumab; Drug: temozolomide
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Cancer
Interventions: Drug: GSK2118436; Drug: GSK1120212; Drug: Other approved anti-cancer agent
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Cancer
Interventions: Drug: pazopanib; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Conditions: Prostate Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male
Intervention: Drug: Abiraterone Acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2013 - Condition: Neoplasms, Breast
Interventions: Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A; Biological: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Breast Cancer
Interventions: Drug: Sorafenib(Nexavar, BAY43-9006) / Capecitabine; Drug: Placebo / Capecitabine
Sponsors: Bayer; Bayer; Onyx Therapeutics, Inc.
Recruiting - verified May 2013 - Condition: Multiple Myeloma
Interventions: Drug: VELCADE; Drug: Lenalidomide; Drug: Dexamethasone; Drug: DVT prophylaxis; Drug: Bisphosphonates; Drug: Liposomal doxorubicin; Drug: Dexamethasone
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center
Recruiting - verified May 2013 - Conditions: Systemic Lupus Erythematosus; Connective Tissue Disease; Autoimmune Disease
Interventions: Drug: LY2127399; Drug: Placebo every 2 weeks; Drug: Placebo every 4 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Multiple Sclerosis, Primary Progressive
Interventions: Drug: ocrelizumab; Drug: Placebo; Drug: methylprednisolone
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Colorectal Cancer
Interventions: Biological: Ramucirumab; Drug: Irinotecan; Biological: Placebo; Drug: Folinic Acid; Drug: 5-Fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company; ImClone LLC
Recruiting - verified May 2013 - Condition: Major Depressive Disorder
Interventions: Drug: LY2216684; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: HIV
Intervention: Drug: Lopinavir/ritonavir
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013 - Condition: Neoplasms, Breast
Interventions: Drug: lapatinib; Drug: trastuzumab; Drug: Aromatase inhibitor; Drug: lapatinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Hypertension
Interventions: Drug: Aliskiren; Drug: Aliskiren; Drug: Aliskiren
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2013 - Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013 - Condition: Vulvodynia
Intervention: Drug: Gabapentin extended-release
Sponsors: University of Tennessee; University of Tennessee; University of Tennessee Health Science Center
Recruiting - verified May 2013 - Condition: Cancer
Intervention:
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; National Cancer Institute (NCI); Fred Hutchinson Cancer Research Center; Nationwide Children's Hospital; M.D. Anderson Cancer Center; University of Southern California; Children's Hospital Medical Center, Cincinnati
Recruiting - verified April 2013 - Condition: Peripheral T-cell Lymphoma
Intervention:
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc
Recruiting - verified May 2013 - Condition: HIV-1 Infections
Interventions: Drug: Darunavir; Drug: ritonavir; Drug: ritonavir; Drug: Darunavir; Drug: ritonavir; Drug: Darunavir; Drug: Darunavir; Drug: Darunavir; Drug: ritonavir; Drug: Darunavir; Drug: ritonavir; Drug: Darunavir; Drug: Darunavir; Drug: ritonavir
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified May 2013 - Condition: Leukaemia, Lymphocytic, Chronic
Interventions: Biological: Ofatumumab; Other: Observation
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Heart Failure With Reduced Ejection Fraction
Interventions: Drug: LCZ696 200 mg BID; Drug: Enalapril 10 mg BID
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2013 - Conditions: HIV Infections; HIV-1
Intervention: Drug: Etravirine
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified May 2013 - Condition: Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Mental Health (NIMH)
Recruiting - verified May 2013 - Condition: HIV Infection
Intervention: Drug: All licensed antiretroviral medications
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); Copenhagen HIV Programme (CHIP) -- Copenhagen, Denmark; Medical Research Council (MRC) Clinical Trials Unit -- London, United Kingdom; The Kirby Institute for Infection and Immunity in Society; The Institute for Clinical Research at the Veterans Affairs Medical Center -- Washington, D.C., USA; French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); German Federal Ministry of Education and Research; NEAT - European AIDS Treatment Network; National Health and Medical Research Council, Australia; National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Mental Health (NIMH); National Institute of Neurological Disorders and Stroke (NINDS); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Abbott; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Merck; Tibotec Pharmaceutical Limited
Recruiting - verified May 2013 - Condition: Chronic Heart Failure
Interventions: Drug: Enalapril monotherapy; Drug: Aliskiren monotherapy; Drug: Aliskiren / Enalapril combination therapy
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2013 - Condition: Hodgkin Lymphoma
Interventions: Drug: Stanford V Chemotherapy; Radiation: Radiation Therapy
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified May 2013 - Condition: Traumatic Brain Injury
Intervention: Drug: Progesterone
Sponsors: Emory University; David Wright
Recruiting - verified May 2013 - Condition: Human Immuno Deficiency (HIV) Infections
Interventions: Drug: TMC278; Drug: Zidovudine; Drug: Abacavir; Drug: Tenofovir disoproxil fumarate; Drug: Lamivudine; Drug: Emtricitabine
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified May 2013 - Conditions: Candidemia; Candidiasis
Interventions: Drug: anidulafungin; Drug: fluconazole
Sponsors: Pfizer; Pfizer
Recruiting - verified October 2012 - Condition: Acute Myeloid Leukemia
Interventions: Drug: Cytarabine; Drug: Daunorubicin; Drug: Etoposide; Drug: Clofarabine
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; Genzyme; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Severe Combined Immunodeficiency; Malignancy, Hematologic; Neuroblastoma; Neoplasm; Mucopolysaccharidosis I
Intervention: Procedure: Venipuncture
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified May 2013 - Condition: Hematopoietic Stem Cell Transplantation
Intervention: Other: Data Collection
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified May 2013 - Conditions: Crohn's Disease; Ulcerative Colitis; Indeterminate Colitis; Inflammatory Bowel Diseases
Interventions: Biological: Anti TNF therapy including infliximab; Drug: No Biologics
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified May 2013 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: Induction Chemotherapy; Drug: Low-Risk Therapy; Drug: High-Risk Therapy; Drug: Intermediate-Risk Therapy
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; University of Florida
Recruiting - verified May 2013 - Conditions: Leukemia, Acute Lymphocytic (ALL); Leukemia, Myeloid, Acute(AML); Leukemia, Myeloid, Chronic(CML); Juvenile Myelomonocytic Leukemia (JMML); Hemoglobinuria, Paroxysmal Nocturnal (PNH); Hodgkin Lymphoma; Lymphoma, Non-Hodgkin (NHL); Myelodysplastic Syndrome (MDS)
Interventions: Device: CliniMACS; Procedure: Stem cell transplantation; Drug: Systemic chemotherapy and antibodies
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified May 2013 - Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine; Drug: Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Neoplasms, Breast; Breast Cancer
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline; North Central Cancer Treatment Group; National Cancer Institute (NCI); Breast International Group; NCIC Clinical Trials Group
Recruiting - verified May 2013 - Condition: HIV Infections
Interventions: Drug: Raltegravir (MK-0518); Drug: Raltegravir (MK-0518); Drug: Raltegravir (MK-0518)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013 - Condition: Lumbar Degenerative Disc Disease
Interventions: Device: DIAM™ Spinal Stabilization System; Procedure: Conservative care
Sponsors: Medtronic Spinal and Biologics; Medtronic Spinal and Biologics
Recruiting - verified April 2013 - Condition: Epilepsies, Partial
Interventions: Drug: Lyrica (pregabalin); Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Conditions: Arthritis, Rheumatoid; Osteoarthritis
Interventions: Drug: celecoxib; Drug: Ibuprofen; Drug: Naproxen
Sponsors: Pfizer; Pfizer; The Cleveland Clinic
Recruiting - verified May 2013 - Conditions: Seizures; Epilepsies, Partial; Epilepsy, Complex Partial; Epilepsy, Generalized; Epilepsy
Interventions: Drug: Placebo; Drug: Vanquix Auto-Injector (Diazepam Injection)
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Condition: Sickle Cell Disease
Intervention:
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; Baylor College of Medicine
Recruiting - verified April 2013 - Condition: HIV Infection
Intervention: Drug: Efavirenz
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Available - verified May 2013
 |
Find Paid Clinical Trials in Memphis, Tennessee |
Clinical Trial Locations 